Morgan Kanwisher, NP
Family · Columbia, SCNPI 1134520836
Payments from drug & device makers
Across 435 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- United Therapeutics Corporation$972
- Sanofi$892
- Regeneron Healthcare Solutions, Inc.$608
- Takeda Pharmaceuticals U.S.A., Inc.$559
- plus $3K from 28 others
What the payments were for
- Consulting fees$2002%
- Food & beverage$9,09197%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 77 | $1,554 |
| GSK | 77 | $1,251 |
| United Therapeutics Corporation | 32 | $972 |
| Sanofi | 30 | $892 |
| Regeneron Healthcare Solutions, Inc. | 21 | $608 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $559 |
| Actelion Pharmaceuticals US, Inc. | 22 | $493 |
| Merck | 22 | $441 |
| Boehringer Ingelheim | 23 | $406 |
| Insmed, Inc. | 23 | $397 |
| Verona Pharma, Inc. | 17 | $220 |
| Bayer | 1 | $200 |
| Mylan Specialty L.p. | 9 | $192 |
| Amgen | 8 | $174 |
| Baxter Healthcare | 7 | $160 |
| Philips North America LLC | 9 | $149 |
| ANI Pharmaceuticals, Inc. | 6 | $122 |
| Advanced Respiratory, Inc | 4 | $76 |
| Novartis | 3 | $63 |
| AbbVie | 3 | $55 |
| Genentech USA, Inc. | 2 | $41 |
| Viatris Specialty LLC | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| BETA Bionics, Inc. | 1 | $27 |
| Shionogi Inc | 1 | $27 |
| Gilead | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Beckman Coulter, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
How this compares
$9,325 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 352 | $270,163 |
| Dupixent PenDupilumab | 65 | $242,931 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 142 | $111,219 |
| Fasenra PenBenralizumab | 18 | $92,690 |
| TezspireTezepelumab-Ekko | 11 | $47,270 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $35,670 |
| Spiriva RespimatTiotropium Bromide | 51 | $30,131 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $19,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $18,325 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $17,782 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 461 | $14,351 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $8,848 |
| Wixela InhubFluticasone Propion/Salmeterol | 48 | $8,598 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,058 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $6,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,251 | $324,158462 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,554 | $176,270211 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $406 | $58,06399 claims |
| MerckDulera | $441 | $4,09412 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $12 | $26414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Columbia
- Mary WilliamsColumbia$67K
- Devon DriverColumbia$21K
- Amanda CharltonColumbia$15K
- Katherine ColemanColumbia$15K
- Melissa RedmondColumbia$13K
- Andrew FieldsColumbia$12K
- Jodi MyersColumbia$12K
- Alaina McClerklinColumbia$11K
- Coty CampbellColumbia$11K
- Patricia DaileyColumbia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.